Core Viewpoint - Shineco, Inc. has announced a public offering of 1,869,160 shares of common stock at a price of $1.07 per share, aiming for gross proceeds of approximately $2 million before expenses [1]. Group 1: Offering Details - The public offering consists of 1,869,160 shares priced at $1.07 each, with total gross proceeds expected to be around $2 million [1]. - Underwriters have a 45-day option to purchase an additional 280,374 shares at the same public offering price [1]. - The offering is anticipated to close on July 15, 2024, pending customary closing conditions [1]. Group 2: Underwriting and Registration - EF Hutton LLC is serving as the sole book-running manager for the offering [2]. - The shares are being offered under an effective shelf registration statement filed with the SEC, which was declared effective on June 10, 2022 [2]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC [2]. Group 3: Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to enhance the quality of life [4]. - The company has developed 33 vitro diagnostic reagents and related medical devices and also produces healthy and nutritious foods [4].

Core Viewpoint - Shineco, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the offering subject to market conditions and no assurance of completion or specific terms [1]. Group 1: Offering Details - The offering includes shares of common stock and pre-funded warrants, all offered by the Company [1]. - The offering is conducted under an effective shelf registration statement on Form S-3, which was filed with the SEC and declared effective on June 10, 2022 [2]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the public offering [2][3]. Group 2: Company Overview - Shineco, Inc. focuses on providing safe, efficient, and high-quality health and medical products and services, aiming to improve the quality of life [5]. - The Company has developed 33 vitro diagnostic reagents and related medical devices and also produces and sells healthy and nutritious foods [5].

Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company") (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offerin ...

The Company believes that its Advanced Proprietary Production Technology Provides it with a Competitive Advantage in the Sector BEIJING, July 10, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that its subsidiary, Fuzhou Meida Health Management Co., Ltd. ("Fuzhou Meida"), has entered into Distribution Agreements (the "Agreements") for its water-soluble phospholipid concentrat ...

BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a res ...

BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non-U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchase ...

BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non- U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchas ...

Core Viewpoint - Shineco Inc. has entered into an Investment Letter of Intent to invest $20 million in Beijing Oriental Meitong Technology Co., Ltd. for 80% equity, aiming to enhance its core competencies and create operational synergies [1][3]. Company Overview - Shineco Inc. focuses on providing innovative diagnostic medical products and related medical devices, with a mission to improve the quality of life through safe and efficient health products [6]. - Meitong Technology specializes in durable medical equipment, offering shared products like wheelchairs and hospital beds, and has established relationships with over 800 hospitals in China, serving more than 12 million patients [2]. Strategic Goals - The acquisition aligns with Shineco's long-term strategy to grow cash flow, expand business operations, and increase corporate valuation [3]. - Meitong Technology plans to diversify its product line and enter new markets, aiming to increase its hospital customer base from 800 to 1,500 within three years and enhance international sales by at least 20% [3][4]. Collaborative Efforts - Both companies will leverage their data on elderly and physically challenged individuals for market analysis and product development, aiming to provide comprehensive solutions in medical devices and rehabilitation care [4]. - Shineco will utilize Meitong Technology's domestic channels to accelerate market expansion and increase product penetration [4]. Financial Incentives - The Investment LOI includes performance benchmarks for Meitong Technology, with potential cash rewards for its management team based on net income growth and patent registrations [5].

Core Viewpoint - Shineco Inc. has entered into a Strategic Cooperation Framework Agreement with Turing Video to jointly develop smart medical products and innovative health solutions for the healthcare market [1][5]. Company Overview - Shineco Inc. is a producer of innovative diagnostic medical products and related medical devices, aiming to improve the quality of life through safe and efficient health products [6]. - Shangkang Life Science, a subsidiary of Shineco, specializes in medical devices for conditions such as bone hyperplasia and rheumatism [2]. Strategic Partnership - The partnership with Turing Video aims to leverage both companies' strengths in biotechnology and AI to create smart healthcare solutions for the elderly [5]. - Turing Video has developed AI products for elderly care, including vital sign monitors and smart fall monitors, and holds over 40 patents [2]. Product Development - Shangkang Life Science plans to develop a system combining miniature biosensors and smart camera equipment to monitor elderly health in real-time, providing alerts for abnormal conditions [3]. - The company also aims to enhance electro-acupuncture devices to improve therapeutic effects for elderly patients [4]. Market Potential - The 'silver economy' in China is projected to reach RMB 30.0 trillion (approximately US$ 4.1 trillion) by 2035, indicating significant market potential for the new smart products targeting geriatric healthcare [5]. - The collaboration is expected to enhance the market competitiveness of Shangkang Life Science's medical products and create a sustainable market presence [4].

Core Viewpoint - Shineco Inc. has entered into a Strategic Cooperation Framework Agreement with Turing Video to jointly develop smart medical products and innovative health solutions for the healthcare market [1][5]. Company Overview - Shineco Inc. is a producer of innovative diagnostic medical products and related medical devices, aiming to improve the quality of life through safe and efficient health products [6]. - Shangkang Life Science, a subsidiary of Shineco, specializes in medical devices for conditions like bone hyperplasia and rheumatism, and has a joint venture with Yangzhou Kangling Medical Co., Ltd. [2]. Strategic Partnership - The partnership with Turing Video aims to leverage both companies' strengths in biotechnology and AI to create smart healthcare solutions for the elderly [5]. - Turing Video has developed AI products for elderly care, including vital sign monitors and smart fall monitors, and holds over 40 patents [2]. Product Development - Shangkang Life Science plans to develop a system combining miniature biosensors and smart camera equipment to monitor elderly health in real-time, providing alerts for abnormal conditions [3]. - The company also aims to enhance electro-acupuncture devices to improve therapeutic effects for elderly patients [4]. Market Potential - The 'silver economy' in China is projected to reach RMB 30.0 trillion (approximately US$ 4.1 trillion) by 2035, indicating significant market potential for the new smart products targeting geriatric healthcare [5]. - The collaboration is expected to enhance the market competitiveness of Shangkang Life Science's medical products and create a sustainable market presence [4].